An observational study in Alcohol Dependence, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2025-03-21.
Sponsored by Otsuka Pharmaceutical Co., Ltd. · Observational
The purpose of this study is to investigate the safety and the prognosis after achieving reduced alcohol intake in patients with alcohol dependence who received treatment for the reduction of alcohol intake in the routine clinical setting in Japan.
1,606 studies on the registry are indexed under Alcoholism; 329 are open to participants now.
This study's enrollment of 533 is above the median of 180 across 173 observational studies indexed under Alcoholism.
Browse Alcoholism studies →Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 140 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with alcohol dependence who are planned to be newly started on nalmefene hydrochloride hydrate for the treatment of reduction of alcohol consumption.
Exclusion Criteria:
Oral administration of nalmefene hydrochloride hydrate
Alcohol Use Disorders Identification Test-Consumption(AUDIT-C)
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Co., Ltd.